Knockout GSDMB, or intracellular-delivered anti-GSDMB through nanocapsules could neutralize the effects of GSDMB, reduce the aggressiveness of HER2 breast cancer, and enhance the sensitivity to trastuzumab (80). This evidence concerns the gene ERBB2 and breast carcinoma.